Label: VARDENAFIL tablet, orally disintegrating

Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.

Vardenafil dosing information

ritonavirritonavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dosage of CYP3A4 substrates, if clinically indicated. rucaparib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamiderufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Vardenafil Side Effects

selpercatinibselpercatinib increases toxicity of vardenafil by QTc interval. selpercatinib increases toxicity of vardenafil by QTc interval. Coadministration of sepiapterin with drugs affecting nitric oxide-mediated relaxation may cause additive vasodilation and further reduce blood pressure. sertralinesertraline and vardenafil both increase QTc interval. sertraline and vardenafil both increase QTc interval. sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of vardenafil by QTc interval. sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of vardenafil by QTc interval.

solifenacinsolifenacin and vardenafil both increase QTc interval.

Can erectile dysfunction be treated with prescription medicines?

pentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Professional resources

posaconazoleposaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors posaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors prednisoneprednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. prednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primaquineprimaquine and vardenafil both increase QTc interval. solifenacin and vardenafil both increase QTc interval.

5.3 Risk of Priapism

olodaterol inhaledvardenafil and olodaterol inhaled both increase QTc interval. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias vardenafil and olodaterol inhaled both increase QTc interval. osilodrostat and vardenafil both increase QTc interval. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval. osimertinib and vardenafil both increase QTc interval.

What is vardenafil, and what is it used for?

ozanimodozanimod and vardenafil both increase QTc interval. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties. ozanimod and vardenafil both increase QTc interval. vardenafil and pasireotide both increase QTc interval. pentobarbitalpentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sorafenibsorafenib and vardenafil both increase QTc interval.

• Vardenafil 10 mg may be used by men over 18 years.
• The medication is not approved for use in women or children.
• May be contraindicated in patients with certain eye conditions.
• Use caution if you have a history of stroke.
• The drug’s chemical action involves improving blood flow.
• It is important to distinguish ED causes before treatment.
• Use only medications prescribed by a healthcare professional.
• Avoid combining with other erectile dysfunction medications.
• Keep medication out of sunlight and moisture.
• Seek emergency medical help for severe side effects.

Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects.

sunitinibsunitinib and vardenafil both increase QTc interval.

• The onset of vardenafil 10 mg is typically 30-60 minutes.
• It can last up to 4-5 hours in some users.
• Vardenafil is contraindicated with certain heart medications.
• Use caution if you have a history of hypotension.
• The tablet may cause mild gastrointestinal upset.
• Do not consume large amounts of alcohol when taking vardenafil.
• Inform your doctor if you experience sudden hearing loss.
• Use only as directed by your healthcare provider.
• Discontinue if you experience persistent erection issues.
• The medication does not increase sexual desire.

sunitinib and vardenafil both increase QTc interval.

What can cause erectile dysfunction?

mitapivatmitapivat decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic index when coadministered with mitapivat. mitapivat decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitotanemitotane decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.

Are you currently using Vardenafil (Levitra, Staxyn)?

mitotane decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nefazodonenefazodone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nefazodone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavirnelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. suzetriginesuzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What happens if I overdose?

primaquine and vardenafil both increase QTc interval. primidoneprimidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by QTc interval. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval.

Patient resources

Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. quininevardenafil and quinine both increase QTc interval. vardenafil and quinine both increase QTc interval. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs. relacorilantrelacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic indexes when coadministered with suzetrigine.

Consider modifying dose of sensitive substrate according to prescribing recommendations.

• Some users may experience mild flickering vision episodes.
• The efficacy of vardenafil varies between individuals.
• The medication is available in various dosage forms.
• Always follow the specific instructions provided.
• Avoid taking vardenafil with high-fat meals to speed absorption.
• Do not take vardenafil if allergic to its ingredients.
• The drug may cause a temporary burning sensation.
• Use caution in patients with a history of priapism.
• Avoid combining vardenafil with certain herbal supplements.
• Consult your doctor about any ongoing health treatments.

suzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use may increase the risk of QTc interval prolongation.

Important Notes

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetronnetupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nevirapinenevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipinenifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Other Interactions

nifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinibnilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/72 hr olanzapineolanzapine and vardenafil both increase QTc interval. olanzapine and vardenafil both increase QTc interval. If concomitant use is unavoidable, adjust the frequency of ECG and electrolyte monitoring.

16.1 How Supplied

Reduce vardenafil dose if coadministered with a strong CYP3A4 inhibitor. relacorilant increases levels of vardenafil by affecting hepatic/intestinal premature ejaculation pills enzyme CYP3A4 metabolism. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec revumenib and vardenafil both increase QTc interval. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec ribociclibribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Related Disease Conditions

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors rifapentinerifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with moderate CYP3A inhibitors. rilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.